CancerICD-10: C81-C85About 89,000 new cases of lymphoma diagnosed annually in the U.S.

Lymphoma

Also known as: Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphatic Cancer

Lymphoma is a cancer of the lymphatic system. The two main types are Hodgkin lymphoma (with Reed-Sternberg cells) and non-Hodgkin lymphoma (a broader, more diverse group). Many forms are highly treatable, with Hodgkin lymphoma having one of the highest cure rates of any cancer.

Last updated November 10, 2026

Understanding Lymphoma

Lymphoma is cancer of lymphocytes, the white blood cells that live in lymph nodes, the spleen, bone marrow and the lymphatic tissue of the gut and skin. It is the most common blood cancer: the American Cancer Society expects about 80,000 new non-Hodgkin lymphomas and roughly 8,700 Hodgkin lymphomas in the United States in 2025, together around 89,000 cases and about 21,000 deaths. Non-Hodgkin lymphoma is a family of more than 80 subtypes under the 2022 World Health Organization classification; diffuse large B-cell lymphoma (about 30 percent) and follicular lymphoma (about 20 percent) are the two largest, and roughly 85 to 90 percent arise from B cells rather than T cells. Hodgkin lymphoma has two age peaks, in the 20s and after 55, while non-Hodgkin lymphoma rises steadily with age and has a median age at diagnosis of about 67. Five-year relative survival is now about 89 percent for Hodgkin lymphoma and 74 percent for non-Hodgkin lymphoma overall, with wide variation by subtype.

Lymphocytes deliberately rearrange and mutate their DNA to make antibodies, which makes them unusually prone to the chromosome errors that start a cancer. Follicular lymphoma is driven by a translocation that switches on the anti-death gene BCL2; Burkitt lymphoma by one that switches on MYC; and about 40 percent of classic Hodgkin lymphoma carries Epstein-Barr virus inside the malignant Reed-Sternberg cells, which make up less than 1 percent of the tumor and recruit a crowd of normal immune cells around them. Behavior splits into two patterns. Aggressive lymphomas (diffuse large B-cell, Burkitt, most T-cell types) can double in size within weeks and are fatal within months if untreated, but they are also the ones chemotherapy can eliminate. Indolent lymphomas (follicular, marginal zone, small lymphocytic) grow over years, often cause no symptoms, usually cannot be eradicated, yet are controlled for decades, and about 2 to 3 percent of follicular lymphomas per year transform into an aggressive type. Fever above 38°C, drenching night sweats and loss of more than 10 percent of body weight in six months are the 'B symptoms' that mark more active disease.

Treatment depends entirely on subtype and stage, and follows National Comprehensive Cancer Network and European Society for Medical Oncology guidelines. Classic Hodgkin lymphoma is treated with ABVD or escalated BEACOPP chemotherapy guided by an interim PET scan, and two trials have moved the standard forward: ECHELON-1 (1,334 patients) showed brentuximab vedotin plus AVD improved six-year overall survival to 93.9 percent from 89.4 percent with ABVD, and SWOG S1826 (994 patients, 2024) found nivolumab plus AVD gave two-year progression-free survival of 92 percent versus 83 percent with brentuximab-AVD, with less toxicity. Diffuse large B-cell lymphoma is treated with six cycles of R-CHOP, which puts about 60 percent of patients into lasting remission; adding polatuzumab (POLARIX, 879 patients) raised two-year progression-free survival from 70 to 77 percent. For early relapse, CAR-T cell therapy has replaced transplant as second-line treatment (ZUMA-7: four-year survival 55 percent versus 46 percent), and bispecific antibodies such as glofitamab and epcoritamab now offer off-the-shelf options. Follicular lymphoma with low tumor burden is often simply watched; when treatment is needed, rituximab alone or with bendamustine typically controls it for many years before another line is required.

No supplement treats lymphoma, and nothing sold as a natural therapy has been shown to shrink a lymph node in people. Where the evidence honestly points is support during treatment. Ginger reduces chemotherapy nausea in a 576-patient trial. Low vitamin D at diagnosis was associated with worse survival in 983 patients with non-Hodgkin lymphoma, so a level is worth checking, though whether correcting it changes outcomes is still being tested. Green tea extract (EGCG) is the one agent with a direct signal: in a Mayo Clinic phase II study of 42 people with early chronic lymphocytic leukemia/small lymphocytic lymphoma, a third had a measurable fall in lymphocyte count, which is interesting but not a treatment. What does not work, and can harm: high-dose antioxidant vitamins during chemotherapy or radiation (a trial in head and neck cancer found higher recurrence with vitamin E and beta-carotene), St John's wort (which speeds the breakdown of many chemotherapy drugs), green tea extract with bortezomib (which it inactivates in laboratory studies), laetrile, high-dose intravenous vitamin C, and 'alkaline' or juice-only diets that cause weight loss when weight is exactly what you need to keep.

The most common mistake during treatment is not telling the oncology team what else you are taking. Surveys find that 60 to 80 percent of people with cancer use a supplement or herbal product, and a large share never mention it, usually because they assume it is harmless or fear disapproval. The problem is pharmacology, not disapproval: rituximab-based regimens, CAR-T and the newer oral drugs all have known interactions, and a well-meant daily green tea extract or turmeric capsule can change drug levels or liver tests in ways that lead to dose reductions or delays. The second mistake happens before diagnosis: letting a painless lump sit for months because it does not hurt. Infection-related nodes are tender and shrink within two to three weeks; a node that is painless, rubbery, larger than 1 cm, still growing after two to four weeks, or sitting above the collarbone needs an ultrasound and usually a biopsy. A fine-needle sample is often not enough to classify lymphoma, so ask for a core or excisional biopsy.

At a Glance

Common symptoms
Painless swelling of lymph nodes in the neck, armpits, or groin, Persistent fatigue, Unexplained fever
Main treatments
Chemotherapy (ABVD for Hodgkin; R-CHOP for diffuse large B-cell lymphoma), Radiation therapy, Immunotherapy (rituximab, brentuximab vedotin, checkpoint inhibitors)
Category
Cancer · About 89,000 new cases of lymphoma diagnosed annually in the U.S.
See a doctor if
Painless, swollen lymph node persisting more than 2 weeks

Symptoms

Painless swelling of lymph nodes in the neck, armpits, or groin
Persistent fatigue
Unexplained fever
Drenching night sweats
Unexplained weight loss (>10% in 6 months)
Itchy skin without visible rash
Shortness of breath or cough if chest nodes are enlarged
Loss of appetite

Causes

  • Genetic mutations in lymphocytes
  • Epstein-Barr virus infection associated with some types
  • Immune suppression (HIV, post-transplant immunosuppression)
  • H. pylori associated with gastric MALT lymphoma

Risk Factors

  • Weakened immune system
  • Prior Epstein-Barr virus infection (for Hodgkin lymphoma)
  • Age (Hodgkin peaks in young adults and over 55; non-Hodgkin increases with age)
  • Family history of lymphoma
  • Autoimmune conditions
  • Exposure to certain pesticides

Diagnosis

  • Excisional lymph node biopsy
  • Immunohistochemistry and flow cytometry
  • PET-CT scan for staging
  • Bone marrow biopsy
  • Blood tests including LDH, CBC, and ESR

Treatment

  • Chemotherapy (ABVD for Hodgkin; R-CHOP for diffuse large B-cell lymphoma)
  • Radiation therapy
  • Immunotherapy (rituximab, brentuximab vedotin, checkpoint inhibitors)
  • CAR-T cell therapy for relapsed disease
  • Stem cell transplant for relapsed disease
  • Watchful waiting for indolent lymphomas

Natural remedies for lymphoma: what the evidence says

Ranked by the strength of human evidence for lymphoma specifically. These sit alongside medical care, not in place of it.

  1. Ginger

    Moderate evidence

    In a US multicenter trial of 576 people on chemotherapy, 0.5 to 1 g of ginger a day for six days, starting three days before each cycle, reduced acute nausea compared with placebo on top of standard antiemetics; the higher 1.5 g dose was no better. A 2013 meta-analysis of seven trials found a benefit for acute but not delayed nausea. It is an add-on to, not a replacement for, prescribed antiemetics.

    Studied dose
    0.5 to 1 g of dried ginger in capsules daily, split into two doses, from 3 days before to 3 days after each chemotherapy cycle.
    Cautions
    Mild antiplatelet effect, so mention it if your platelets are low or you take anticoagulants; can cause heartburn. Stop a week before surgery or central line placement.
  2. Vitamin D

    Preliminary evidence

    In 983 newly diagnosed non-Hodgkin lymphoma patients at Mayo Clinic, half were vitamin D insufficient, and those with diffuse large B-cell or T-cell lymphoma who were low had roughly 1.4 to 2 times the risk of relapse or death. Laboratory work suggests vitamin D improves rituximab's ability to recruit immune cells. Randomized evidence that supplementing improves survival is still lacking, so this is about correcting a documented deficiency, not treating the cancer.

    Studied dose
    Test first; 1,000 to 2,000 IU vitamin D3 daily, or a clinician-directed higher course if 25-hydroxyvitamin D is below 20 ng/mL.
    Cautions
    Some lymphomas raise blood calcium on their own, and high doses in that setting are dangerous. Keep the oncology team informed and avoid more than 4,000 IU a day without monitoring.
  3. Green Tea Extract (EGCG)

    Preliminary evidence

    In a Mayo Clinic phase II trial, 42 people with early-stage, untreated chronic lymphocytic leukemia/small lymphocytic lymphoma took 2,000 mg of a standardized EGCG extract twice daily for up to six months; 31 percent had a sustained fall of 20 percent or more in lymphocyte count and most of those with enlarged nodes saw them shrink by half, but nobody went into remission and it has never been compared with treatment. It is the closest thing to a direct anti-lymphoma signal from a natural product, and it remains only a signal.

    Studied dose
    Studied dose: 2,000 mg Polyphenon E (about 1,000 mg EGCG) twice daily with food.
    Cautions
    Doses above about 800 mg EGCG a day have caused liver injury; check liver enzymes. EGCG blocks bortezomib in laboratory studies and should not be combined with it, and it reduces iron and folate absorption.
  4. L-Glutamine

    Preliminary evidence

    Oral glutamine has been tested for the mouth and gut lining damage (mucositis) that follows chemotherapy and transplant conditioning, because gut cells use it as fuel. Trials are small and mixed: some show less severe oral mucositis and fewer days of pain, others show no difference, and meta-analyses find a modest reduction in mucositis severity with low certainty. It does not change survival.

    Studied dose
    10 g dissolved in water, swished and swallowed, two to three times daily during the mucositis-risk window of each cycle.
    Cautions
    Cancer cells also consume glutamine and some oncologists prefer to avoid it during active treatment, so ask first. Avoid with liver or kidney failure.
  5. Omega-3 Fish Oil

    Preliminary evidence

    Weight and muscle loss during lymphoma treatment worsen tolerance of chemotherapy. Fish oil providing about 2 g of EPA a day stabilized weight and lean mass in several small trials of people with cancer-related weight loss, but a Cochrane review judged the evidence insufficient to recommend it routinely, and no trial is specific to lymphoma.

    Studied dose
    Fish oil supplying about 2 g EPA daily, taken with meals.
    Cautions
    Can reduce platelet function; discuss it if platelets are low or you are on anticoagulants, and stop before procedures. Fishy burps and loose stools are common.

What matters day to day

  • Keep moving through treatment: 150 minutes a week of walking plus two short resistance sessions reduces cancer-related fatigue by a moderate amount in meta-analyses and preserves the muscle that chemotherapy and steroids strip away.
  • Treat a fever of 38°C (100.4°F) or higher during chemotherapy as an emergency: when neutrophils fall below 500 per microliter an infection can become sepsis within hours, so call the oncology line immediately rather than waiting until morning.
  • Get the inactivated flu shot each year and ask about pneumococcal and shingles vaccines before treatment starts, but avoid live vaccines during and for at least 6 to 12 months after rituximab, because the drug wipes out the B cells that make antibodies.
  • Stop smoking: it multiplies the lung damage from bleomycin and chest radiation and the risk of second cancers, which are the leading cause of death in long-term Hodgkin survivors.
  • Keep a survivorship schedule after treatment: women who had chest radiation before 30 need breast screening from 8 years after treatment or age 25, anthracycline recipients need periodic heart checks, and neck radiation calls for a yearly thyroid test.

Prevention

  • No known way to prevent most lymphomas
  • Reduce HIV risk through safe practices
  • Treat H. pylori to prevent gastric MALT lymphoma

When to See a Doctor

  • Painless, swollen lymph node persisting more than 2 weeks
  • Unexplained fever, night sweats, or weight loss
  • Persistent fatigue or itching without identifiable cause
  • A known lymph node enlargement is growing

Frequently Asked Questions

References

  1. American Cancer Society. Key Statistics for Non-Hodgkin Lymphoma (2025)View source
  2. Ansell SM, Radford J, Connors JM, et al.. Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma (ECHELON-1). New England Journal of Medicine (2022)
  3. Herrera AF, LeBlanc M, Castellino SM, et al.. Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma (SWOG S1826). New England Journal of Medicine (2024)
  4. Tilly H, Morschhauser F, Sehn LH, et al.. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma (POLARIX). New England Journal of Medicine (2022)
  5. Westin JR, Oluwole OO, Kersten MJ, et al.. Survival with axicabtagene ciloleucel in large B-cell lymphoma (ZUMA-7). New England Journal of Medicine (2023)
  6. Drake MT, Maurer MJ, Link BK, et al.. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. Journal of Clinical Oncology (2010)
  7. Shanafelt TD, Call TG, Zent CS, et al.. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer (2013)
  8. Ryan JL, Heckler CE, Roscoe JA, et al.. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Supportive Care in Cancer (2012)
  9. National Cancer Institute. Adult Hodgkin Lymphoma Treatment (PDQ), Patient Version (2025)
  10. MedlinePlus, National Library of Medicine. Lymphoma (2024)View source

Related Conditions

Related Reading

Have questions about Lymphoma?

Ask Mother Nature AI for personalized, evidence-based guidance.

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.